IFP Advisors’s IGM Biosciences IGMS Stock Holding History

IFP Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8	Closed	-$562	–	3013
2020 Q3	$1K	Buy	+8	New	+$474	﹤0.01%	2643

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

IFP Advisors's IGMS Position: Q4 2020 in Review

IFP Advisors sold out of IGM Biosciences (IGMS) in Q4 2020, closing a stake of 8 shares — an estimated $562 sold.

IFP Advisors first reported a position in IGMS in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 107 funds tracked by Wall St. Rank hold IGMS as of Q4 2020.

IFP Advisors reported no remaining IGM Biosciences position as of Q4 2020 after selling out during the quarter.
IFP Advisors sold 8 IGM Biosciences shares in Q4 2020, an estimated $562.
IFP Advisors first reported a position in IGM Biosciences in Q3 2020 and held it in 1 quarter.
IFP Advisors's IGM Biosciences position peaked at $1K in Q3 2020.
107 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2020.

Based on IFP Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.